The PC-free data at the lowest dose exceeded expectations, with 50% of patients achieving drug-free responses. This de-risks the PC-free strategy and expands the addressable market. Watch for initial SLE PC-free data at EULAR (June 3-6, 2026) and higher-dose PV data in 2H26. The automated manufacturing data supports scalability and cost reduction. The myositis BLA submission in 2027 is the next major catalyst.
Price Chart
Executive Summary
Cabaletta Bio presented new clinical data at ASGCT 2026 showing that 2 of 4 refractory pemphigus vulgaris patients achieved drug-free responses through 6 months at the lowest dose of rese-cel without preconditioning, and initial automated manufacturing data from the Cellares Cell Shuttle platform met all release specifications with comparable in vivo behavior. The company also highlighted its registrational cohort in myositis with a planned 2027 BLA submission and expects PC-free data from SLE in 1H26 and higher-dose PV data in 2H26.
Key Facts
- 2 of 4 refractory PV patients at the lowest PC-free rese-cel dose maintained drug-free compelling clinical responses through 6 months of follow-up (data cut-off April 2, 2026).
- 3 of 4 PC-free patients experienced complete peripheral B cell depletion; CAR T expansion kinetics were similar to preconditioned patients.
- First 2 GMP doses of rese-cel manufactured on the automated Cellares Cell Shuttle met all release specifications with on-time delivery and comparable in vivo behavior.
- Myositis registrational cohort (n=17) initiated with planned 2027 BLA submission; 3 of 3 DM patients with sufficient follow-up achieved major TIS responses at Week 16.
- Safety profile in first 40 preconditioned patients: 95% had no CRS or Grade 1 CRS (fever); 95% had no ICANS, supporting outpatient administration.
- Initial PC-free SLE data expected in 1H26 at EULAR 2026; higher-dose PC-free PV data anticipated in 2H26.
- Company raised $150M extending runway into mid-2027.
Financial Impact
No revenue reported; $150M capital raise extends runway into mid-2027. Positive clinical data supports pipeline valuation with myositis BLA planned for 2027.
Risk Factors
- PC-free data is from only 4 patients at the lowest dose; higher doses may show different safety/efficacy profiles.
- ASyS patients showed time-limited responses in some cases, suggesting potential durability challenges in certain subtypes.
- Competition from other CD19-CAR T programs in autoimmunity (e.g., Kyverna, BMS) could limit market share.
- Regulatory pathway for PC-free regimen may require additional clinical data beyond current plans.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759138-26-000024 |
| Document: caba-20260514.htm | 0001759138-26-000024 |
| Document: caba-ex99_1.htm | 0001759138-26-000024 |
| Document: 0001759138-26-000024-index-headers.html | 0001759138-26-000024 |
| Document: 0001759138-26-000024-index.html | 0001759138-26-000024 |
| Document: 0001759138-26-000024.txt | 0001759138-26-000024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $2.00 (−31.27%) |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $2.00 (−30.80%) |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $2.00 (−26.20%) |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $2.00 (−26.20%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | $2.00 (−33.55%) |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | $2.00 (−44.13%) |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | $2.00 (−45.50%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | $2.00 (+44.60%) |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $2.00 (−44.60%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $2.00 (−44.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access